Which of the following intravenous anaesthetic agent pharmacokinetic does not change on renal and hepatic dysfunction –
**Core Concept**
The pharmacokinetics of intravenous anesthetic agents can be significantly altered in patients with renal or hepatic dysfunction, affecting their distribution, metabolism, and elimination. Understanding the changes in pharmacokinetics is crucial for safe and effective anesthesia management.
**Why the Correct Answer is Right**
Propofol is a unique intravenous anesthetic agent with a pharmacokinetic profile that is minimally affected by renal or hepatic dysfunction. Its distribution is primarily determined by lipid solubility, and its elimination is mainly through redistribution, not metabolism or excretion. As a result, propofol's pharmacokinetics remain relatively unchanged in patients with renal or hepatic dysfunction.
**Why Each Wrong Option is Incorrect**
**Option A:**
Many intravenous anesthetic agents, such as barbiturates (e.g., thiopental) and benzodiazepines (e.g., midazolam), undergo hepatic metabolism and have altered pharmacokinetics in patients with liver dysfunction.
**Option B:**
Opioids, such as fentanyl and morphine, are metabolized by the liver and their clearance is reduced in patients with hepatic dysfunction, leading to increased serum levels and potential toxicity.
**Option C:**
Muscle relaxants like rocuronium and succinylcholine are metabolized and excreted by the kidneys, and their clearance is reduced in patients with renal dysfunction, leading to prolonged neuromuscular blockade.
**Clinical Pearl / High-Yield Fact**
In patients with renal or hepatic dysfunction, it's essential to choose an anesthetic agent with a pharmacokinetic profile that is minimally affected by these conditions, such as propofol.
**Correct Answer: C. Propofol**